CHEK1 and ovarian cancer: Notably, elevated baseline levels of activated ATR and CHK1 have been detected in several PARP-inhibitor-sensitive ovarian cancer cells, indicating a high level of preexisting RS that made these cells highly dependent on the ATR/CHK1 pathway with increased sensitivity to ATR inhibitor therapy [150, 180].